Global Markets Direct’s, 'Cellulite - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cellulite, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cellulite. Cellulite - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Cellulite. - A review of the Cellulite products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cellulite pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Cellulite. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Cellulite pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Cellulite - Pipeline Review, H1 2013 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Cellulite Overview 6 Therapeutics Development 7 An Overview of Pipeline Products for Cellulite 7 Cellulite Therapeutics under Development by Companies 9 Mid Clinical Stage Products 10 Comparative Analysis 10 Early Clinical Stage Products 11 Comparative Analysis 11 Pre-Clinical Stage Products 12 Comparative Analysis 12 Cellulite Therapeutics - Products under Development by Companies 13 Companies Involved in Cellulite Therapeutics Development 14 Auxilium Pharmaceuticals, Inc. 14 Halozyme Therapeutics 15 Helix BioMedix, Inc. 16 Futura Medical plc. 17 Global Health Ventures Inc. 18 Easton Pharmaceuticals Inc. 19 Cellulite - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Drug Profiles 25 collagenase clostridium histolyticum - Drug Profile 25 Product Description 25 Mechanism of Action 25 RandD Progress 25 HTI-501 - Drug Profile 28 Product Description 28 Mechanism of Action 28 RandD Progress 28 POS-002 - Drug Profile 29 Product Description 29 Mechanism of Action 29 RandD Progress 29 EP-005 - Drug Profile 30 Product Description 30 Mechanism of Action 30 RandD Progress 30 Cellulite Therapeutics - Drug Profile Updates 31 Cellulite - Product Development Milestones 39 Featured News and Press Releases 39 Jan 31, 2012: Interim Data From Phase I Study Of HTI-501 Support Commencement Of Phase II Portion Of Clinical Trial 39 Jan 26, 2012: Auxilium Announces First Cohort Of Patients Dosed In XIAFLEX Phase Ib Cellulite Study 39 Dec 05, 2011: Futura Medical Develops CRF100 For Cellulite Treatment 40 Sep 28, 2011: Halozyme Begins Clinical Trial With HTI-501 In Women With Edematous Fibrosclerotic Panniculopathy 41 Aug 31, 2011: Auxilium And BioSpecifics Announce Plans To Develop Additional Indications Using XIAFLEX 41 May 19, 2008: Halozyme Therapeutics Presents Pre-Clinical Studies on Dermal Remodeling With HTI-501, a Lysosomal Proteinase 42 Appendix 43 Methodology 43 Coverage 43 Secondary Research 43 Primary Research 43 Expert Panel Validation 43 Contact Us 44 Disclaimer 44
List of Tables
Number of Products Under Development for Cellulite, H1 2013 7 Products under Development for Cellulite - Comparative Analysis, H1 2013 8 Number of Products under Development by Companies, H1 2013 9 Comparative Analysis by Mid Clinical Stage Development, H1 2013 10 Comparative Analysis by Early Clinical Stage Development, H1 2013 11 Comparative Analysis by Pre-Clinical Stage Development, H1 2013 12 Products under Development by Companies, H1 2013 13 Auxilium Pharmaceuticals, Inc., H1 2013 14 Halozyme Therapeutics, H1 2013 15 Helix BioMedix, Inc., H1 2013 16 Futura Medical plc., H1 2013 17 Global Health Ventures Inc., H1 2013 18 Easton Pharmaceuticals Inc., H1 2013 19 Assessment by Monotherapy Products, H1 2013 20 Assessment by Stage and Route of Administration, H1 2013 22 Assessment by Stage and Molecule Type, H1 2013 24 Cellulite Therapeutics - Drug Profile Updates 31
List of Figures
Number of Products under Development for Cellulite, H1 2013 7 Products under Development for Cellulite - Comparative Analysis, H1 2013 8 Products under Development by Companies, H1 2013 9 Mid Clinical Stage Products, H1 2013 10 Early Clinical Stage Products, H1 2013 11 Pre-Clinical Stage Products, H1 2013 12 Assessment by Monotherapy Products, H1 2013 20 Assessment by Route of Administration, H1 2013 21 Assessment by Stage and Route of Administration, H1 2013 22 Assessment by Molecule Type, H1 2013 23 Assessment by Stage and Molecule Type, H1 2013 24